Bempikibart Delivers Promising Hair Regrowth in Alopecia Trial, Sending Q32 Bio Stock Soaring
The experimental treatment showed meaningful hair regrowth and a favorable safety profile.
/ 3 items
#QTTB↓
Mizuho Turns Positive on Q32 Bio’s Bempikibart, Initiates Coverage with Outperform Rating
Mizuho sees Q32 Bio upside with $14 target vs ~$5.50, boosted by bempikibart alopecia drug progress and 2026 data.
Q32 Bio Sells Drug Asset to Akebia Therapeutics
Q32 Bio sells complement inhibitor ADX-097 to Akebia for $12M upfront plus milestone payments up to $592M, extending cash runway to mid-2027 while focusing on alopecia treatment.